Colorectal Cancer Rates Are Rising Again Across Nearly Every Age Group Under 70
After 20 years of decline, US colorectal cancer incidence rose in 2023, with increases now reaching adults well beyond the young. Researchers point to birth cohort effects.
Riepilogo
Colorectal cancer is climbing again in the United States after more than two decades of steady decline. A new analysis of National Cancer Institute data, published in NEJM Evidence, found that the age-adjusted incidence rate fell from 55.2 cases per 100,000 people in 2000 to 36.7 in 2022, then ticked up to 38.3 in 2023. The rise is no longer confined to younger adults. Rates are now increasing in nearly every age group through ages 65 to 69. The researchers suggest a birth cohort effect: people born in the 1960s and later appear to carry higher risk that becomes more visible as they age. The steepest jump was among adults 45 to 49, at 12.76% per year from 2019 to 2023, likely driven partly by lowered screening start ages. The causes of the broader trend remain unknown, and the findings raise questions about future healthcare burden.
Riepilogo Dettagliato
Colorectal cancer is the second leading cause of cancer deaths in the United States and the leading cause among adults younger than 50. For more than 20 years, overall incidence fell, largely credited to screening that finds and removes precancerous polyps. That progress now appears to be reversing, which matters for anyone planning for a long, healthy life.
Researchers led by Caitlin Murphy at the University of Chicago analyzed National Cancer Institute incidence data from 2000 through 2023. The age-adjusted rate dropped from 55.2 per 100,000 in 2000 to 36.7 in 2022, then rose to 38.3 in 2023. This was the first overall increase in over two decades. Rates are now rising in every age group through ages 65 to 69.
Murphy attributes the pattern to a birth cohort effect, in which people born in the same era share exposures that become more apparent as they age. Those born in the 1960s and later seem to face elevated risk as they enter middle age and beyond. The sharpest rise was in adults 45 to 49, up 12.76% annually from 2019 to 2023. Much of that is likely explained by guideline changes that lowered the recommended screening start age, which detects more existing cancers.
Practically, the findings reinforce the value of staying current with colorectal screening at the recommended ages, and of not ignoring symptoms such as blood in the stool, persistent bowel changes, unexplained weight loss, or anemia, even in younger adults. Lifestyle factors linked to colorectal risk, including physical activity, fiber intake, limiting processed meat and alcohol, and maintaining healthy body composition, remain sensible priorities.
Several caveats apply. The underlying causes of the rise remain unknown. Part of the increase may reflect more screening rather than a true rise in disease. One year of uptick, 2023, is a limited basis for long-term conclusions, and the birth cohort explanation is an inference rather than a proven mechanism.
Risultati Principali
- US colorectal cancer incidence rose from 36.7 to 38.3 per 100,000 in 2023, the first overall increase in over 20 years.
- Rates are now rising across nearly every age group through ages 65 to 69, not only in younger adults.
- Adults 45 to 49 saw a 12.76% annual increase from 2019 to 2023, partly reflecting earlier screening guidelines.
- Researchers suggest a birth cohort effect, with people born from the 1960s onward carrying higher risk as they age.
- The causes of the rising trend remain unknown, highlighting the need for continued screening and risk research.
Metodologia
This is a news summary of an epidemiological analysis of National Cancer Institute incidence data from 2000 to 2023, published in NEJM Evidence. The source is a university press release, and the journal is reputable. The evidence is observational and descriptive rather than causal.
Limitazioni dello Studio
The article is truncated and does not identify the causes of the rise, and the birth cohort explanation is a hypothesis. Increased screening may inflate recent incidence, particularly at ages 45 to 49. Verify detailed age-specific trends, stage at diagnosis, and mortality data in the original NEJM Evidence paper.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti:
